ABBV · News · 20260827N

Competition and Market Position

AbbVie Inc. · 2026-08-27 · Importance 40 · Surprise 42

China’s drug regulator approved Johnson & Johnson’s oral psoriasis treatment Icotyde on August 27, 2026. The approval intensifies competition in China’s moderate-to-severe plaque psoriasis market, where Icotyde will compete with AbbVie’s injectable treatments and products from Bristol Myers Squibb. The Chinese market includes more than 8.4 million patients with the condition, while analysts have described Icotyde as having blockbuster potential.